Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (7–36) amide (GLP‐1) is released from the gut into the circulation after meals and is the most potent physiological insulinotropic hormone in man. In contrast to presently available therapeutic agents for non‐insulin‐dependent diabetes mellitus (NIDDM), GLP‐1 has the advantages of both suppressing glucagon secretion and delaying gastric emptying. We report the first chronic study of subcutaneous (s/c) GLP‐1 treatment in NIDDM. Five patients with poorly controlled NIDDM were entered into a six‐week, double‐blind crossover trial. Each received three weeks treatment with s/c GLP‐1 40 nmol or saline, given three times a day immediately before meals. A standardized test meal was given at the beginning and end of each treatment period. GLP‐1 reduced plasma glucose area under the curve (AUC) following the standard test meal by 25% (AUC, 0–180 mins, GLP‐1 start of treatment 482.2 ± 38.2 vs. saline start of treatment 635.7 ± 45.4 mmol min L−1, F = 16.4, P < 0.02). The beneficial effect of GLP‐1 on plasma glucose concentration was fully maintained for the three‐week treatment period. Plasma glucagon levels were significantly lower for 60 min postprandially after GLP‐1 treatment. In this group of patients there was no significant increase in postprandial insulin levels with GLP–1. We have demonstrated a significant improvement in postprandial glycaemic control with s/c GLP‐1 treatment that was fully maintained over a three‐week treatment period. GLP‐1 improves glycaemic control even in the absence of an insulinotropic effect and is a potential treatment for NIDDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Cited by
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Metadata
- Authors
- TODD, J. F., WILDING, J. P. H., EDWARDS, C. M. B., KHAN, F. A., GHATEI, M. A., & BLOOM, S. R.
- Venue
- European Journal of Clinical Investigation
- Publisher
- Wiley
- Published
- 1997-06
- Volume
- 27
- Issue
- 6
- Pages
- 533-536
- ISSN
- 0014-2972 (ISSN-L)
- 1365-2362
- OpenAlex
- W2103960782
- Cited by
- 87
- References
- 1
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus. https://app.cochat.ai/papers/10.1046/j.1365-2362.1997.1490691.x
- The paper
- TODD, J. F., WILDING, J. P. H., EDWARDS, C. M. B., KHAN, F. A., GHATEI, M. A., & BLOOM, S. R. (1997). Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus. European Journal of Clinical Investigation. https://doi.org/10.1046/j.1365-2362.1997.1490691.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.